Form 4: Orchestra BioMed Director John Mack Awarded Significant Equity Compensation

Orchestra BioMed Holdings, Inc. Director John Mack was granted 12,422 Restricted Stock Units and 36,797 stock options on June 24, 2025, as part of his compensation.

Summary

• Director John Mack of Orchestra BioMed Holdings, Inc. (OBIO) was awarded equity compensation on June 24, 2025.
• The award includes 12,422 Restricted Stock Units (RSUs) of Common Stock, with a reported acquisition price of $0.
• Additionally, Mr. Mack received 36,797 stock options with an exercise price of $3.22 per share.
• Both the RSUs and stock options will vest in a single installment on the earlier of the one-year anniversary of the grant date (June 24, 2025) or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent on Mr. Mack's continuous service.
• Following these transactions, Mr. Mack beneficially owns 25,286 shares of Common Stock and 36,797 stock options.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The filing reports routine equity compensation for a director, which is generally a neutral to slightly positive event as it aligns interests. There are no overtly negative or positive financial results or strategic announcements.

Positives

• The equity awards align the interests of Director John Mack with those of shareholders, incentivizing long-term performance.
• The grant of stock options provides a future incentive for the director to contribute to the company's stock price appreciation.

Negatives

• The issuance of new equity (RSUs and potential shares from options) could lead to minor dilution for existing shareholders upon vesting and exercise.

Risks

• The vesting of RSUs and stock options is subject to the reporting person's continuous service, meaning the awards could be forfeited if service ceases before vesting.
• The value of the stock options is dependent on the future market price of Orchestra BioMed Holdings, Inc. common stock exceeding the exercise price of $3.22.

Future Outlook

The document indicates future vesting events for the awarded equity, contingent on the director's continuous service through the one-year anniversary of the grant date or the 2026 Annual Meeting of Stockholders.

Industry Context

This Form 4 filing reflects a standard practice of public companies to compensate directors and executives with equity, aligning their interests with long-term shareholder value. Such compensation is common across various industries, particularly in biotechnology and medical device sectors like Orchestra BioMed, to attract and retain talent.

Comparison to Industry Standards

• The grant of Restricted Stock Units and stock options to a director is a common form of equity compensation in publicly traded companies, particularly in the life sciences sector.
• While specific compensation amounts vary widely based on company size, performance, and individual roles, the structure of these awards (e.g., vesting over time, performance-based where applicable, and alignment with Rule 10b5-1 plans) is consistent with industry best practices for executive and director compensation aimed at aligning interests with long-term shareholder value.
• No specific comparable companies or projects are mentioned in this filing to allow for a direct numerical comparison.

Stakeholder Impact

• Shareholders: Minor potential for dilution upon vesting and exercise of equity awards. However, it also signals alignment of director interests with shareholder value.
• Employees: No direct impact mentioned for general employees.

Next Steps

• Vesting of 12,422 RSUs and 36,797 stock options on the earlier of June 24, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continuous service.
• Potential exercise of 36,797 stock options by June 24, 2035.

Key Dates

Recommendation

Keywords

Orchestra BioMed Holdings, OBIO, SEC Form 4, Insider Trading, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Director Compensation, John Mack, Executive Compensation, Corporate Governance